This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	MicroRNA-132 (miR-132)	A study in mice suggests that inhibiting miR-132 could help treat cancer. In a mouse xenograft model of human breast cancer, vessel-targeted delivery of an antagomir against miR-132, called anti-miR-132, reduced angiogenesis and tumor burdens compared with delivery of scrambled anti-miRNA ($p < 0.05$ for both). Next steps include evaluating modified and stabilized forms of anti-miRNAs to determine whether they could be useful when directly injected to block tumor and ocular angiogenesis in mice.	Patent application filed covering use in an undisclosed indication; available for licensing from the University of California, San Diego Technology Transfer Office	Anand, S. <i>et al. Nat. Med.</i> ; published online Aug. 1, 2010; doi:10.1038/nm.2186 Contact: David A. Cheresch, University of California, San Diego, La Jolla, Calif. e-mail: dcheresh@ucsd.edu
SciBX 3(31); doi:10.1038/scibx.2010.951 Published online Aug. 12, 2010				